Dr Mario Guerrieri is a Radiation Oncologist with GenesisCare in Victoria. He has subspecialty interest in GU malignancies particularly focused on the care of men with prostate cancer. He is actively involved in clinical trials in all stages of prostate cancer. He has actively recruited to ENZARAD and DASL-HiCaP, is currently involved in the use of AI in men with intermediate risk grouping prostate cancer via the ASTUTE clinical trial, and is an author on multiple trials run via GenesisCare in Victoria. In addition to his patient centred care, he is the medical director of the Victorian division of GenesisCare and sits on the board of GenesisCare as a Doctor Director.

Tim Showalter, MD, MPH, is Chief Medical Officer at ArteraAI a Professor of Radiation Oncology at the University of Virginia and. At ArteraAI, he oversees clinical development and evidence generation for multimodal AI biomarkers, including the ArteraAI Prostate Test, which is guideline-recommended and CMS-reimbursed. At UVA, he maintains a clinical practice and previously led research programs in prostate, breast, and gynecologic cancers, publishing over 190 peer-reviewed articles. Dr. Showalter has led NCI-funded clinical trials, founded a medical device startup (Advaray) acquired by CQ Medical, and is active in national research groups focused on outcomes and brachytherapy.

Catherine is a Prostate Cancer Clinical Nurse Consultant, working for GenesisCare. Catherine has an extensive history in cancer nursing, working in haematology and bone marrow transplant, medical oncology and radiation therapy. Catherine has worked in multiple health services and has pioneered changes and implementation of new services. Within her current role, Catherine has created Nurse-Led services in partnership with consultants. Catherine has a passion for patient centric care, advocacy and improving health literacy.

I am a Clinical Assistant Professor in the Department of Radiation Oncology at Konkuk University Medical Center. After completing residency training at Asan Medical Center, I pursued subspecialty fellowships in genitourinary, gynecologic, and head and neck cancers at Asan Medical Center and Samsung Medical Center. I am currently a Ph.D. candidate in Radiation Oncology and have authored multiple peer-reviewed publications in the field. My academic and clinical focus lies in delivering evidence-based, patient-centered radiotherapy, with a continued commitment to advancing oncologic outcomes through research and multidisciplinary collaboration.

Dr. Niluja Thiru (B.Sc., MBBS, FRANZCR, MPH, PhD) is a Staff Specialist in Radiation Oncology and holds a Conjoint Senior Lecturer position at The University of Sydney. She completed her medical studies at The University of Queensland and speciality training in Australia before undertaking the Windeyer Brachytherapy Fellowship at Mount Vernon Cancer Centre, UK. Following this she completed her PhD with the Translational Radiobiology group at The University of Manchester on hypoxia gene expression signatures in prostate cancer. Her research interests primarily focus on radiation response biomarkers, with a particular emphasis on their application in genitourinary and gynaecological cancers.

Dr Aviral Singh is the Clinical Head of Theranostics & Nuclear Medicine at GenesisCare Australia and based in Perth, Western Australia. Aviral is an active research physician and Investigator for several multicentre clinical trials in Theranostics. He has published over 45 peer-reviewed scientific papers and serves on the Guest Editorial Board for the Frontiers journals in Endocrinology and Nuclear Medicine. His recognitions include the prestigious ‘Ones to Watch’ at SNMMI 2022, USA, inclusion in the Global Physician Honor Roll of GenesisCare in 2022, listing as a Leading World Physician of IAHCP in 2017, in addition to receiving best scientific paper awards at the SNMMI 2016 and the ICRT in 2019 and 2024. He has presented keynote and invited lectures at several scientific society meetings nationally and internationally. Aviral serves as a member of the Governing Body of the World Association of Radiopharmaceutical and Molecular Therapy.

Dr. Srinivas is a research-oriented nuclear medicine physician-scientist who completed both an M.D. and a Ph.D. at the University of California, Irvine in 2002. He completed his residency training in nuclear medicine in 2006 at the University of Pennsylvania in Philadelphia. Dr. Srinivas then joined the Cleveland Clinic Department of Nuclear Medicine where he worked for 9 years and served as the Dept Vice-Chairman for 4 years. In 2016, he was recruited to join the faculty at Stanford University. He had a brief stint in industry and served as the Chief Medical Officer of Sirtex Medical, Inc. the world’s largest manufacturer of Y-90 microspheres for radioembolization. In 2019 he joined the faculty at UPMC in Pittsburgh, and in 2023 he returned as a faculty member to UC Irvine. He currently is an Associate Professor in the Dept of Radiological Sciences, the Director of Theranostics and Clinical Molecular Imaging Research, and the Chief of Nuclear Medicine. He is an active PI of several theranostic clinical trials, and his research interests include imaging with novel PET tracers, alpha theranostics, and image-based dosimetry.

Dr Cristian Udovicich is a Radiation Oncologist with GenesisCare from Melbourne. He has completed subspecialty fellowships at the Sunnybrook Odette Cancer Centre, University of Toronto in Canada and Peter MacCallum Cancer Centre in Melbourne. In Toronto, his primary research included multiple prospective trials of stereotactic body radiotherapy and HDR brachytherapy for prostate cancer. He has been a recipient of the Thomas Baker Fellowship by the Royal Australian and New Zealand College of Radiologists.